Argentina has made an important step forward to protect local production of generics of an essential medicine to treat Hepatitis C. This brings significant advantages for Public Programs which procure the medicines. Por: Julia Varela Buenos Aires, December 4, 2017. In Argentina, the INPI (National Institute of Industrial Property) rejected GILEAD PHARMASSET LLC patent application
The decision, for which the Fundación GEP contributed with/to decisive arguments, paves the way to generic versions to facilitate access to treatments. Por: Julia Varela May 23, 2017 - In a resolution that means a step forward in safeguarding the right to health, Argentina’s patent office (the National Institute of Industrial Property - INPI) forced
The Argentinian National Institute of Industrial Property (INPI, by its acronym in Spanish) signed a bilateral agreement with the US Patent Office on February 13th that includes reciprocal acceptance of patenting results of both offices. The news are grave and serious as the "Patent Prosecution Highway Between USPTO and INPI-Argentina" effectively repeals the Argentine Patent
Por: Julia Varela BUENOS AIRES, February 14, 2017 - The GEP Foundation and Intiative for Medicines, Access and Knowledge (IMAK) filed yesterday an opposition at the National Institute of Industrial Property (INPI) to the patent request by multinational pharmaceutical company Gilead on the base compound of sofosbuvir, a drug that represents the cure for hepatitis C. The action means a great step to
Buenos Aires, Argentina – 16, 17 and 18 November 2016 15 years of the Doha Declaration on TRIPS and Public Health: Health Safeguards as effective tools to protect Health and exercise Sanitary Sovereignty. Fundación GEP invites to the International Congress on Access to Medicines, Medical Technologies and Human Rights that will take place in Buenos Aires, Argentina. The
September 15th 2016 - Press release Fundación Grupo Efecto Positivo (FGEP) - Associação Brasileira Interdisciplinar de AIDS (ABIA) - Grupo de Trabalho sobre Propriedade Intelectual (GTPI) United Nations’ High Level Panel on Access to Medicines Report released: Big Pharma’s court cases in Brazil & Argentina threaten to dismantle the national laws considered as important public health safeguards
The Argentine Community of People Living with HIV requested the rejection of a patent for an essential HIV/AIDS medicine. If the Argentine Patent Office does grant the this request, Argentina could produce generic versions at a lower cost representing a potential saving of over US$11 million. Argentina April 13th, 2015.- The Grupo Efecto Positivo Foundation (FGEP) in collaboration with the Argentine
Buenos Aires, August 27th 2015 - Members of Grupo Efecto Positivo Foundation (FGEP) accompanied by other civil society organizations and representatives held a direct action during the 2015 Hepatitis International Symposium organized by Fundación Huesped. The action aimed to denounce monopolies and high prices of drugs to treat hepatitis C and took place during the presentation of Dr.
BUENOS AIRES - On World Viral Hepatitis Day, Fundación Grupo Efecto Positivo (FGEP) held a meeting with officials from Argentina’s Ministry of Health, articulating and coordinating actions and strategies that promote access to sofosbuvir, an essential drug for Hepatitis C treatment. The need for joint action originates from the great challenge both Argentina and Latin